Mass Biosciences, a biotech startup with ambitions in space, has launched what it calls a historic experiment to gather data in orbit. The company believes microgravity can unlock new insights into treating challenging diseases, particularly cognitive decline and cancer.
The experiment, now underway, is designed to collect biological data in a low-Earth orbit environment. This marks the first time the startup has tested its approach outside the planet's atmosphere, a move it sees as essential for advancing its therapeutic platform.
Alzheimer's disease affects an estimated 55 million people worldwide, with no cure currently available. By studying cellular behavior in microgravity, Mass Biosciences hopes to identify novel drug targets that could slow or reverse cognitive decline—a market projected to exceed $10 billion over the next decade.
If successful, this approach could open a new frontier for biotech research, proving that space-based experimentation has practical medical applications on Earth. However, the field remains nascent; few startups have demonstrated viable therapies from orbital studies, and regulatory pathways for space-derived biologics are undefined.
Countering the optimism, critics note that space-based biotech experiments are notoriously expensive and have yet to yield a single approved treatment. The high cost of launch and data retrieval also raises questions about scalability and return on investment for early-stage ventures like Mass Biosciences.